Drug Development and Immunity - Pharmacist Digest

STAT+: AltruBio raises $225 million to develop ulcerative colitis drug and other immune checkpoint enhancers

STAT

MAY 21, 2024

Checkpoint inhibitors, drugs that unleash the immune system, have turned into blockbuster therapies that have transformed outcomes for some patients with deadly cancers.

Immunity

STAT+: Chasing CAR-T, biotech finds its next gold rush in autoimmune disease

STAT

OCTOBER 14, 2024

Biotech investors have been buzzing around new areas of drug development this year, such as the red-hot obesity market. billion to companies developing treatments for conditions in which the body’s own immune system goes haywire, attacking healthy cells and tissues and causing widespread damage.

Immunity

FDA authorizes new drug to protect immune compromised from Covid-19

STAT

MARCH 22, 2024

The Food and Drug Administration on Friday authorized a new antibody to protect immunocompromised individuals against Covid-19. The drug, known as Pemgarda and marketed by the biotech Invivyd, is the first such drug to become available since the agency pulled AstraZeneca’s Evusheld off the market in January 2023.

Immunity

AbbVie to buy immune drug developer Landos

BioPharma Dive

MARCH 25, 2024

Worth about $138 million upfront, the deal is another example of pharma interest in new drugs for inflammatory conditions like Crohn’s.

Immunity

STAT+: Biogen joins immunology wave with $1.15 billion acquisition

STAT

MAY 22, 2024

Biogen is joining the industry’s fervor over immune and inflammatory disease drug development with a new acquisition. HI-Bio, which is based in San Francisco, is developing therapies for immune-mediated diseases like primary membranous nephropathy and IgA nephropathy, both of which impact kidney function.

Immunity

2nd NSCLC Drug Development Summit

pharmaphorum

JUNE 15, 2022

The 2nd NSCLC Drug Development Summit returns for its second year to unite biopharma and academic leaders during an exciting era of personalized medicine. Improve your drug development rationale across all lines of NSCLC and address challenges when moving therapies forward. Progress sequencing and combination approaches.

Drug Development

Lilly buys oral immune drug developer Dice Therapeutics for $2.4B

BioPharma Dive

JUNE 20, 2023

The deal adds to recent M&A activity as well as signals pharma’s continued interest in pills for inflammatory conditions, which are meant to approach the potency of injectable therapies.

Immunity

Aviceda, QUB to develop next-generation glyco-immune therapeutics

Pharmaceutical Technology

APRIL 10, 2023

Aviceda Therapeutics (Aviceda) has entered into a strategic partnership with the Patrick G Johnston Centre for Cancer Research at Queen’s University Belfast (QUB) for the development of next-generation glyco-immune therapeutics. The company strengthens the translational research collaboration between the US and Ireland.

Immunity

Tackling immune-mediated disease with CAR Tregs

European Pharmaceutical Review

OCTOBER 20, 2022

Recognising the potential of CAR T cells to act as highly targeted therapeutics, several biotechnology companies – including Sangamo Therapeutics – have established development pipelines of CAR T regulatory cells (Tregs) that aim to tackle immune?mediated What are Tregs and how are they applicable to immune-mediated disease?

Immunity

Capturing transporter structure paves the way for drug development

World Pharma News

MAY 23, 2023

Jude Children’s Research Hospital and the University of Texas Southwestern Medical Center studied the structure and function of a transporter involved in cancer and immunity. The findings, published in Cell, have implications for drug development.

Drug Development

Drug Development Immunity Immunization Hospitals

STAT+: Dreams of cancer vaccines are becoming more real. Here are 9 scientists making it happen

STAT

OCTOBER 29, 2024

But many other modes of immunotherapy for cancer were approved first — checkpoint blockade drugs like Keytruda and engineered immune cell therapies like Yescarta. Cancer vaccines may also be able to help train the immune system to recognize and kill cancers related to viruses like HPV.

Vaccines

Vaccines Immunization Immunity Drug Development

Collaboration to chart AI-generated map of the immune system

Outsourcing Pharma

DECEMBER 21, 2020

A partnership between Immunai and 10x Genomics will use artificial intelligence to create a map of the immune system to help accelerate drug development.

Immunity

Triple Negative Breast Cancer Drug Development Digital Summit

pharmaphorum

FEBRUARY 10, 2021

Given the large unmet clinical need in this oncology indication and aligned with recent clinical trial progress, the Triple Negative Breast Cancer (TNBC) Drug Development Digital Summi t has been created to provide insight into industry- and academic-led clinical programs developing immune checkpoint, DDR inhibitor, ADC and other novel agents.

Drug Development

Drug Development Immunization Immunity Vaccines

4th Antigen Specific Immune Tolerance Summit

pharmaphorum

DECEMBER 4, 2020

The 4 th Antigen Specific Immune Tolerance Digital Summit (ASIT) brings together industry representatives from the fields of autoimmunity, allergy, immuno-oncology and transplantation to tackle the complexities behind autoimmune disorders head on. This is the industry’s definitive antigen specific drug development forum.

Immunity

Immunity Immunization Medical Schools Drug Development

BioMed X and Sanofi partner to leverage AI for drug development

Pharmaceutical Technology

OCTOBER 25, 2022

BioMed X has entered a research partnership with Sanofi to leverage artificial intelligence (AI) for drug development. This team will focus on creating a versatile computational platform that can precisely forecast the first-in-class drug candidates’ efficacy in virtual patient groups.

Drug Development

Drug Development Diabetes Immunity Immunization

Jade, another biotech spinout of Paragon, to merge with Aerovate

BioPharma Dive

OCTOBER 31, 2024

The immune disease drug developer expects to raise $300 million in a private financing set to close before its combination with the struggling Aerovate.

Immunity

Foundery, a new biotech venture firm, sets out to speed early immune drug research

BioPharma Dive

AUGUST 22, 2023

Billing itself as both a scientific and investment partner, Foundery aims to provide research grants and drug development support to researchers developing new immunotherapies.

Immunity

J&J, Rallybio partner on drug development for rare fetal condition

BioPharma Dive

APRIL 10, 2024

The biotech is working on a preventive therapy for the immune disorder, known as FNAIT for short, while J&J is studying its drug nipocalimab as a treatment.

Drug Development

FREE – Gastrointestinal Cancer Drug Development Digital Summit

pharmaphorum

OCTOBER 13, 2021

The Gastrointestinal Cancer Drug Development Summit is the only biopharma-led conference dedicated to identifying and progressing therapeutic opportunities in targeted and immunotherapies, ADCs, and precision oncology to address the large unmet clinical need in GI cancers. Register for your FREE ticket here: [link].

Drug Development

Upstream prices $255M IPO in bid to challenge Amgen, AstraZeneca asthma drug

BioPharma Dive

OCTOBER 10, 2024

The offering will fund testing of a potential rival to Amgen’s Tezspire and is already the sixth for an immune drug developer this year, the most since 2021.

Immunity

Upstream prices $255M IPO in bid to challenge Amgen, AstraZeneca asthma drug

BioPharma Dive

OCTOBER 10, 2024

The offering will fund testing of a potential rival to Amgen’s Tezpire and is already the sixth for an immune drug developer this year, the most since 2021.

Immunity

Welcome to the 2nd Chronic HBV Drug Development Summit

pharmaphorum

MARCH 10, 2022

With a tight lens on late translational through to phase II clinical progress; the 2nd Chronic HBV Drug Development Summit is dedicated to advancing direct antiviral and immunotherapy pipelines in combination therapy paradigms. The post Welcome to the 2nd Chronic HBV Drug Development Summit appeared first on.

Drug Development

Drug Development Immunity Immunization Vaccines

Absci and M2GEN partner to expedite cancer drug development

Pharmaceutical Technology

APRIL 5, 2023

Absci stated that this collaboration combines AI drug creation technology and oncology bioinformatics, thereby reducing the time and cost of cancer drug development. Initially, the company will use its reverse immunology technology to search the database for antibodies from patients showing strong immune responses.

Drug Development

Povetacicept by Alpine Immune Sciences for Systemic Lupus Erythematosus: Likelihood of Approval

Pharmaceutical Technology

MARCH 2, 2023

Povetacicept is under clinical development by Alpine Immune Sciences and currently in Phase I for Systemic Lupus Erythematosus. According to GlobalData, Phase I drugs for Systemic Lupus Erythematosus have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. Buy the report here.

Immunity

Immunity Immunization Pharmaceutical Companies Pharmaceutical Companies

STAT+: New antiviral works against coronaviruses in mice, but human testing will have to wait

STAT

MAY 22, 2024

Startlingly effective shots quickly helped immunize a large portion of the population — at least initially, and in high-income countries. During the Covid-19 pandemic, vaccines were the main line of defense. Antiviral treatments were not as impactful.

Vaccines

Vaccines Immunization Immunity Drug Development

Non-Small Cell Lung Cancer Drug Development Summit

pharmaphorum

APRIL 20, 2021

The Non-Small Cell Lung Cancer (NSCLC) Drug Development Summit is the definitive industry-led forum for drug development in the largest solid tumor indication. The post Non-Small Cell Lung Cancer Drug Development Summit appeared first on. View the event guide now for more details!

Drug Development

Drug Development Medical Schools Immunity Immunization

STAT+: Cancer vaccines gain momentum, after years of disappointing results

STAT

APRIL 10, 2024

The promise has long been an affordable, personalized cancer vaccine that could train the immune system to recognize proteins from cancer cells and, subsequently, destroy the tumor.

Vaccines

Vaccines Immunization Immunity Drug Development

How GLP-1’s moved from research labs to national TV

STAT

MARCH 28, 2024

Today, we’re reading about the world’s costliest drug, plus we learn about immune senescence and a potential cause for a kidney autoimmune disease. Sign up to get it in your inbox here. It’s Meghana. Read the rest…

Immunity

Immunity Immunization Drug Pricing Drug Development

Opinion: Lessons learned from the deadly combination of sepsis and Covid-19

STAT

DECEMBER 22, 2022

Sepsis, a deadly overreaction of the immune system to infection, has befuddled clinicians and researchers for decades. Covid-19 made things worse.

Immunity

STAT+: Early data are promising for autoimmune disease drug from Roivant Sciences’ Immunovant

STAT

SEPTEMBER 26, 2023

Results released Tuesday from an early study of an autoimmune disease drug from Roivant Sciences’ Immunovant showed the treatment could reduce the levels of a key immune marker in the blood, a promising signal.

Immunization

STAT+: Argenx antibody fails study in platelet-destroying autoimmune disorder, derailing expansion plans

STAT

NOVEMBER 28, 2023

The negative study, called ADVANCE-SC, was the second of two clinical trials involving the Argenx drug called efgartigimod in patients with primary immune thrombocytopenia (ITP), a debilitating condition that destroys blood-clotting platelets. Argenx shares were down 12% in early trading.

Immunization

Takeda agrees to develop active immunotherapy for Alzheimer’s

European Pharmaceutical Review

MAY 14, 2024

Takeda and AC Immune SA have agreed a global option and license agreement for a potential first-in-class Abeta-targeting active immunotherapy for Alzheimer’s. AC Immune’s related immunotherapies targeting Abeta are part of the deal, including the Alzheimer’s treatment ACI-24.060.

Immunity

Blackstone wants in on red-hot immunology market

STAT

MAY 16, 2024

The need-to-know this morning Biogen and Ionis Pharmaceuticals are ending their development of an experimental drug for ALS based on results of a Phase 1/2 trial. Novartis said it’s met all tender offer conditions to acquire German biotech Morphosys.

Immunity

Immunity Immunization Drug Pricing Drug Development

After a slow start for expensive CAR-T therapies, drug developers revisit oral therapies for blood cancer

pharmaphorum

DECEMBER 23, 2022

There’s been huge progress in treatments for blood cancer in recent years – but drawbacks of expensive CAR-T cell and injected antibody therapies have led drug developers to look at novel oral therapies as patient-friendly alternatives.

Drug Development

Drug Development Immunization Immunity Hospitals

STAT+: Pharmalittle: We’re reading about drug shortages, what drugmakers didn’t tell Alzheimer’s trial patients and more

STAT

OCTOBER 24, 2024

Among the basic and life-saving medicines for which shortages continue to be problematic are Rho(D) immune globulin, pain and sedation medications, and ADHD pills. So far this year, 95 new shortages were reported, a drop from 156 in 2023, although 50% of active shortages have persisted for two or more years.

Immunization

Immunization Immunity Drug Pricing Drug Development

Bringing the promise of immunotherapy to a broader population

pharmaphorum

OCTOBER 17, 2022

When James P Allison and Tasuku Honjo were awarded the Nobel Prize for Medicine in 2018 for their discovery of cancer therapy through inhibition of negative immune regulation, it shone a light on decades of research into recruiting the immune system to fight cancer. That’s what makes them such a tricky detective mystery!

Immunity

The future of AI drug discovery & development in immunology and GPCR research

pharmaphorum

SEPTEMBER 16, 2022

A mere six months ago Verily launched the study with Sosei Heptares – a global leader in GPCR structure-based drug design – with an aim to “prioritise protein targets for therapeutic targeting in immune-mediated disease”. It also bodes well for improving clinical trial success rates.

Immunization

Understanding the tumour micro-environment – the pharmaphorum podcast

pharmaphorum

OCTOBER 6, 2022

As our understanding of oncology has increased, it’s become clear that each cancer consists of much more than just the tumour cell – a whole ecosystem of vessels, immune cells, and connective tissues form the tumour micro-environment (TME).

Immunity

Gilead snaps up MiroBio and its checkpoint agonists for $405m

pharmaphorum

AUGUST 5, 2022

MiroBio was formed in 2019 to develop checkpoint agonist antibodies for autoimmune and inflammatory disorders that can be used to apply the “natural brakes” of the immune system. 7 integrin, with three candidates in early-stage clinical development.

Immunization

Will Novartis provide new oral option for chronic hives?

European Pharmaceutical Review

AUGUST 9, 2023

As a highly selective BTK inhibitor, remibrutinib “has the potential to be a first-in-class, oral treatment for people living with CSU whose symptoms are refractory despite use of antihistamines,” stated Dr Shreeram Aradhye, President of Global Drug Development and Chief Medical Officer at Novartis.

Immunization

Immunization Immunity Pharmaceutical Companies Pharmaceutical Companies

Preventative approach could reduce immunotherapy side effects

European Pharmaceutical Review

JANUARY 4, 2024

Immunotherapy drugs like teclistamab can result in potentially fatal side effects, including CRS and immune cell-associated neurotoxicity syndrome (ICANS). An overactive immune response [is] the hallmark of CRS,” Landgren added. The drug tocilizumab for example, has been used historically to treat CRS from immunotherapies.

Immunization

Immunization Immunity Hospitals Drug Development

STING & TLR Targeting Therapies Summit

pharmaphorum

APRIL 12, 2021

This is the definitive drug development forum for research teams to investigate how to modulate the cGAS-STING and Toll-like receptor (7/8/9) pathways both as monotherapies and as adjuvants in combinatorial approaches. View the full event guide now. The post STING & TLR Targeting Therapies Summit appeared first on.

Immunity